We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
The FDA’s review of GlaxoSmithKline (GSK) and XenoPort’s restless legs syndrome drug Solzira has been pushed back to Feb. 9 after GSK submitted a risk evaluation and mitigation strategy (REMS).